Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:CTXR NASDAQ:THAR OTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$3.95+0.5%$4.46$3.02▼$6.47$21.27M-0.76118,621 shs78,703 shsCTXRCitius Pharmaceuticals$1.21+0.8%$1.41$0.65▼$15.25$20.41M1.35465,642 shs159,960 shsTHARTharimmune$3.14+0.3%$2.59$0.95▼$9.08$17.81M1.5631.26 million shs721,361 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+0.51%+1.28%+7.34%-5.95%-39.32%CTXRCitius Pharmaceuticals+0.83%-1.63%-5.47%+38.35%-90.87%THARTharimmune+0.32%-14.67%+137.88%+143.41%+6.44%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$3.95+0.5%$4.46$3.02▼$6.47$21.27M-0.76118,621 shs78,703 shsCTXRCitius Pharmaceuticals$1.21+0.8%$1.41$0.65▼$15.25$20.41M1.35465,642 shs159,960 shsTHARTharimmune$3.14+0.3%$2.59$0.95▼$9.08$17.81M1.5631.26 million shs721,361 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate+0.51%+1.28%+7.34%-5.95%-39.32%CTXRCitius Pharmaceuticals+0.83%-1.63%-5.47%+38.35%-90.87%THARTharimmune+0.32%-14.67%+137.88%+143.41%+6.44%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 3.00Buy$26.25564.56% UpsideCTXRCitius Pharmaceuticals 2.50Moderate Buy$53.004,280.17% UpsideTHARTharimmune 3.50Strong Buy$17.00441.40% UpsideULURULURU 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ULUR, CING, THAR, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$61.00 ➝ $62.008/13/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.008/8/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$2.32 per shareN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/AULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$15.55M-$4.10N/AN/AN/AN/A-232.16%-132.07%11/6/2025 (Estimated)CTXRCitius Pharmaceuticals-$39.14MN/A0.000.97N/AN/A-60.03%-33.83%N/ATHARTharimmune-$12.20M-$6.10N/A∞N/AN/A-1,239.20%-365.06%11/6/2025 (Estimated)ULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ULUR, CING, THAR, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CINGCingulate-$0.82-$1.09-$0.27-$1.09N/AN/A8/14/2025Q2 2025THARTharimmune-$0.58-$0.64-$0.06-$0.64N/AN/A8/12/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A1.521.52CTXRCitius PharmaceuticalsN/A0.470.14THARTharimmuneN/A1.171.17ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%CTXRCitius Pharmaceuticals16.88%THARTharimmune1.16%ULURULURUN/AInsider OwnershipCompanyInsider OwnershipCINGCingulate4.04%CTXRCitius Pharmaceuticals10.70%THARTharimmune10.01%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate205.41 million5.19 millionNot OptionableCTXRCitius Pharmaceuticals2017.01 million15.19 millionOptionableTHARTharimmune25.69 million5.12 millionNot OptionableULURULURU230.57 million30.24 millionNot OptionableULUR, CING, THAR, and CTXR HeadlinesRecent News About These CompaniesJourney Beyond inch closer to$300m Uluru deal with Voyages Indigenous Tourism AustraliaSeptember 12 at 9:34 AM | ntnews.com.auNJetstar drops massive $120 spring sale to popular tourist destinationSeptember 11 at 5:02 AM | skynews.com.auSUluru’s only resort set to land new private equity-backed ownerSeptember 11 at 5:02 AM | afr.comJetstar launches NT sale to grow Top End and Red Centre tourismSeptember 10 at 11:56 PM | travelweekly.com.auTJetstar drops insane $129 sale to hotspotSeptember 10 at 6:56 PM | news.com.auNJetstar Unveils Big NT Sale to Boost TourismSeptember 10 at 6:56 PM | miragenews.comMUluru, Fuji and the Great Wall: The most amazing sights to look out for mid-flightSeptember 6, 2025 | telegraph.co.ukVANLIFE in the Red Centre, Part 2 - Outback Australia | Uluru, Kata Tjuta and Kings Canyon | Ep. 14September 6, 2025 | msn.comInfluencers Spark Outrage Over Uluru Photo ControversySeptember 3, 2025 | msn.comSix influencers went on a trip to Uluru and totally missed the pointSeptember 1, 2025 | metro.co.ukM‘Deeply educational’: Influencers defend Uluru trip after backlash over ‘insensitivity’August 31, 2025 | dailytelegraph.com.auDUluru Dialogue pushing to ‘reignite’ Indigenous constitutional recognitionAugust 31, 2025 | skynews.com.auSUluru Dialogue vow to renew recognition fightAugust 29, 2025 | theaustralian.com.auYouTubers Find Out Uluru's Rules Are No JokeAugust 27, 2025 | msn.comOnboard Qantas’ Brand New A220 Over the Australian OutbackAugust 26, 2025 | msn.com‘Not an attractive destination’: Couple films Uluru, commits ’20 fineable offences’August 26, 2025 | msn.comTourists shocked when ordered to delete photos of oft-visited area — and they could have faced a hefty fine: ‘We weren’t aware about that’August 25, 2025 | msn.com‘20 fineable offences’: Aussie couple’s shock email three months after Uluru tripAugust 25, 2025 | news.com.auNTravel vloggers given ’20 fines’ after filming during visit to historic world site – how you can avoid the same mistakeAugust 25, 2025 | thesun.co.ukUluru tourists ordered to delete photos of sacred sites - and they could have faced a hefty fine: ‘We weren’t aware about that’August 25, 2025 | skynews.com.auSNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025Costco and Ross: 2 Ways to Play the Consumer DivideBy Chris Markoch | August 24, 2025Williams-Sonoma Q2 Results Prove Its Buy-and-Hold QualityBy Thomas Hughes | August 27, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025ULUR, CING, THAR, and CTXR Company DescriptionsCingulate NASDAQ:CING$3.95 +0.02 (+0.51%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.96 +0.01 (+0.38%) As of 09/12/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Citius Pharmaceuticals NASDAQ:CTXR$1.21 +0.01 (+0.83%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.20 -0.01 (-0.83%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Tharimmune NASDAQ:THAR$3.14 +0.01 (+0.32%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.18 +0.03 (+1.11%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
